We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

73 hedge funds and large institutions have $1.81B invested in Verve Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 30

6% more funds holding

Funds holding: 69 → 73 (+4)

1.03% less ownership

Funds ownership: 81.71% → 80.68% (-1%)

19% less capital invested

Capital invested by funds: $2.25B → $1.81B (-$437M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+4
Holders Change %
+5.8%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
34
Increased
16
Reduced
13
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$71.6M
2
AIM
ARK Investment Management
Florida
+$42.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$37M
4
BlackRock
BlackRock
New York
+$24.4M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.3M
2
Millennium Management
Millennium Management
New York
-$24.7M
3
LGM
Logos Global Management
California
-$18.5M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$14.9M
5
NHAS
Novo Holdings A/S
Denmark
-$11.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
76
Alyeska Investment Group
Illinois
– -$6.03M -100,000 Closed
O
77
OrbiMed
New York
– -$6.03M -100,000 Closed
SCM
78
Suvretta Capital Management
New York
– -$6.03M -100,000 Closed
PCH
79
Polar Capital Holdings
United Kingdom
– -$3.92K -65,000 Closed
HF
80
HRT Financial
New York
– -$3.75M -62,159 Closed
TA
81
TRB Advisors
New York
– -$3.62M -60,000 Closed
PVI
82
Pura Vida Investments
New York
– -$3.58M -59,393 Closed
Balyasny Asset Management
83
Balyasny Asset Management
Illinois
– -$2.88M -47,749 Closed
EGI
84
EAM Global Investors
California
– -$2.41M -40,055 Closed
GPP
85
Great Point Partners
Connecticut
– -$2.11M -35,000 Closed
PCM
86
Pinz Capital Management
New York
– -$2.1M -34,800 Closed
Squarepoint
87
Squarepoint
New York
– -$1.88M -31,253 Closed
MCM
88
Moore Capital Management
New York
– -$1.83M -30,446 Closed
Susquehanna International Group
89
Susquehanna International Group
Pennsylvania
– -$1.72M -28,525 Closed
EI
90
EAM Investors
California
– -$1.71M -28,413 Closed
LP
91
LMR Partners
United Kingdom
– -$1.51M -25,000 Closed
UAM
92
UAS Asset Management
New York
– -$1.51M -25,000 Closed
ACM
93
Asymmetry Capital Management
California
– -$1.49M -24,790 Closed
MWNA
94
Marshall Wace North America
New York
– -$1.11M -18,451 Closed
Qube Research & Technologies (QRT)
95
Qube Research & Technologies (QRT)
United Kingdom
– -$767K -12,730 Closed
Jane Street
96
Jane Street
New York
– -$572K -9,492 Closed
Tudor Investment Corp
97
Tudor Investment Corp
Connecticut
– -$476K -7,904 Closed
VF
98
Virtu Financial
New York
– -$411K -6,822 Closed
PHK
99
Point72 Hong Kong
Hong Kong
– -$343K -5,700 Closed
MS
100
Maven Securities
Jersey
– -$361K -5,556 Closed
1 2 3
4
5

VERV Hedge Fund Activity: Q3 2021 in Review

73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2021, worth a combined $1.81B — down 19% from $2.25B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new VERV positions and 30 closed out — a net gain of 4 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $71.6M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $41.3M sold.

  • 73 institutional investors held Verve Therapeutics (VERV) as of Q3 2021, up from 69 in Q2 2021.
  • Funds reported $1.81B of Verve Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
  • 34 funds opened new Verve Therapeutics positions in Q3 2021 and 30 closed out, a net change of +4 holders.
  • The largest Verve Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $71.6M added.
  • The largest Verve Therapeutics seller in Q3 2021 was T. Rowe Price Associates, an estimated $41.3M sold.

Based on aggregated 13F filings for Q3 2021.